Reports of Practical Oncology and Radiotherapy最新文献

{"title":"A single-institution retrospective review of patients treated with single-fraction 28 Gy SBRT to lung tumors.","authors":"Benson Wan, Vanessa Di Lalla, Tanner Connell, Neil Kopek, Marie Duclos, Bassam Abdulkarim, Sergio L Faria","doi":"10.5603/rpor.111334","DOIUrl":"10.5603/rpor.111334","url":null,"abstract":"<p><strong>Background: </strong>Single-fraction stereotactic body radiotherapy (SBRT) has been used to treat lung tumors. However, there is heterogeneity in the prescribed dose. We performed a single-institution, retrospective review to assess the outcomes associated with single-fraction 28 Gy SBRT to cancers in the lung.</p><p><strong>Materials and methods: </strong>A chart review was performed on all patients treated with 28 Gy in 1 fraction to the lung in our institution between February 2022 and April 2023. Patient and tumour characteristics were obtained. Outcomes pertaining to local control, and acute and late toxicities occurring after treatment were obtained from radiological reports and patient charts.</p><p><strong>Results: </strong>130 patients were reviewed and analyzed. The median follow-up in this cohort was 22 months. 81% of the patients were treated for a primary lung tumour. Estimated Kaplan-Meier 1- and 2-year local control rates were 95.7% (primary: 97.9%, metastases: 89.1%) and 86.9% (primary: 87.6%, metastases: 76.3%), respectively. 21% of patients experienced acute grade 1-2 toxicities, most commonly fatigue and temporary chest wall pain. 18% of patients experienced late grade 1-2 toxicities, most commonly asymptomatic pneumonitis and chest wall pain. There was no reported grade 3 or higher acute or late toxicities.</p><p><strong>Conclusions: </strong>Our review supports the safety and value of 28 Gy delivered in one fraction. Prospective trials with long-term follow-up are needed to define the role and optimal dose of single-fraction ablative SBRT to lung tumors.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 3","pages":"375-379"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric predictors of erectile dysfunction in Moroccan men treated with volumetric modulated arc therapy for prostate cancer.","authors":"Ihsane Skitioui, Karima Nouni, Salma Ichou, Rachida Laraichi, Amine Lachgar, Hanan Elkacemi, Tayeb Kebdani, Khalid Hassouni","doi":"10.5603/rpor.111331","DOIUrl":"10.5603/rpor.111331","url":null,"abstract":"<p><strong>Background: </strong>Erectile dysfunction (ED) is a frequent and impactful side effect of prostate cancer radiotherapy. Data on the relationship between radiation dose to the penile bulb (PB) and ED severity in North African populations remain limited. This study aimed to assess ED prevalence and severity in Moroccan men treated with volumetric modulated arc therapy (VMAT) and identify associated clinical and dosimetric predictors.</p><p><strong>Materials and methods: </strong>A retrospective analysis was performed on 52 Moroccan patients treated with VMAT for localized or locally advanced prostate cancer (2021-2024). Erectile function was evaluated using the Sexual Health Inventory for Men (SHIM) score. Analyzed dosimetric variables included PB mean dose, PB V30, PB V50, PB V60, and doses to 25-90% of the PB volume (PB D25, PB D50, PB D75, PB D90). Statistical methods included ANOVA, Pearson correlation, ROC curve analysis, and multivariate logistic regression.</p><p><strong>Results: </strong>Moderate to severe ED was found in 65.4% of patients. Strongest correlations with SHIM score were seen for PB D25 (r = -0.47), PB mean dose (r = -0.45), PB V30 (r = -0.41), and PB D50 (r = -0.41). ROC analysis identified PB V30 > 64.9% and PB D50 > 38.7 Gy as optimal cutoffs for predicting ED. ISUP grade was significantly associated with ED severity (p = 0.007), while TNM stage and D'Amico classification were not. No significant association was observed with hypertension, diabetes, or smoking.</p><p><strong>Conclusions: </strong>This study highlights the importance of PB dosimetry in predicting post-radiotherapy ED. PB V30 and PB D50 emerged as reliable predictors, underscoring the need to integrate PB constraints in VMAT planning to preserve erectile function in prostate cancer survivors.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 3","pages":"349-357"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel insights into phase angle in breast cancer - stage-specific associations between body composition and metabolic age.","authors":"Janusz Doś, Monika A Rosochowicz-Kamińska, Mirosława Mocydlarz-Adamcewicz, Igor Piotrowski, Maciej Górecki, Magdalena Górska-Doś","doi":"10.5603/rpor.110816","DOIUrl":"10.5603/rpor.110816","url":null,"abstract":"<p><strong>Background: </strong>Body composition parameters are critical in determining overall health in breast cancer (BC) patients. Phase angle (PhA), measured via non-invasive Bioelectrical Impedance Analysis (BIA), is emerging as a superior biomarker compared to body mass index (BMI). This study examined the relationship between PhA and body composition across different BC stages.</p><p><strong>Materials and methods: </strong>Bioelectrical impedance analysis was performed in 833 BC patients who were stratified into early-, intermediate-, and advanced-stage groups based on TNM (tumour, node, metastasis) classification and treatment approach. Body composition parameters, including water compartments, muscle mass, and metabolic age, were analysed and compared between groups.</p><p><strong>Results: </strong>Phase angle differed significantly across cancer stages (p = 0.0065) and was correlated with age independently of stage (p = 0.0033). Differences in extracellular water (ECW; p = 0.0392), intracellular water (ICW; p = 0.0014), total body water (TBW; p = 0.0069), and muscle mass (p = 0.0085) were observed between stages. Phase angle was significantly associated with ICW across all stages, with additional correlations found between PhA and predicted muscle mass (PMM), as well as TBW, in early- and intermediate-stage patients. Metabolic age varied by cancer stage (p = 0.0052) and influenced PhA independently of stage (p = 0.1906), with higher PhA observed in patients metabolically older than their chronological age.</p><p><strong>Conclusions: </strong>Phase angle is closely linked to key body composition parameters, particularly water and muscle content, with some associations varying by cancer stage. This is the first study to report a stage-independent relationship between PhA and metabolic age in BC patients, warranting further investigation into its clinical relevance.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 3","pages":"389-399"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruptured metastatic pleuropulmonary blastoma simulating cerebral hemorrhage.","authors":"Aleksandra Osińska, Claudia Sieńko, Milena Kędra, Andrzej Materniak, Magdalena M Woźniak","doi":"10.5603/rpor.111336","DOIUrl":"10.5603/rpor.111336","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 3","pages":"461-463"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and efficacy of simultaneously integrated boost radiotherapy in head and neck cancer treatment.","authors":"Gyöngyi Kelemen, Emese Fodor, Melinda Csenki, Melánia Fuszkó, Árpád Puskás, Emőke Borzási, Zsuzsanna Besenyi, Viktor Paczona, Ferenc Borzák, László Szakács, Róbert Paczona, Zoltán Varga, Judit Oláh, Katalin Hideghéty","doi":"10.5603/rpor.111325","DOIUrl":"10.5603/rpor.111325","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy (RT) plays a crucial role in managing head and neck tumors. A key challenge is balancing optimal tumor control with the preservation of healthy tissues. Our study aimed to evaluate the key benefits and complications of head and neck RT using simultaneously integrated boost (SIB) compared to conventional fractionation.</p><p><strong>Materials and methods: </strong>This study included patients with head and neck cancers who received definitive or postoperative RT between September 2022 and October 2023 at the Department of Oncotherapy, University of Szeged. A total of 66 patients were analyzed, with 33 receiving SIB and 33 treated with sequential boost (SB). All patients underwent adaptive RT with or without concurrent cisplatin or cetuximab therapy. Demographic and pathological data were comparable between the groups. Acute toxicities, local control outcomes at three months post-RT, and tumor volume changes at two-thirds of the RT course were assessed.</p><p><strong>Results: </strong>No significant differences were observed in dysphagia, radiomucositis, and xerostomia between the two groups. The incidence of grade 2-3 radiodermatitis was significantly higher in the SB group (42.4% <i>vs</i>. 15.6%; p = 0.01). and therapeutic breaks were more frequent with SB compared to SIB. There was no significant difference in local tumor response rates between the groups during and after the RT. Biological effective dose (BED) calculations suggest a slightly lower probability of late side effects with the SIB technique.</p><p><strong>Conclusions: </strong>The SIB technique can be safely and effectively used in head and neck RT, offering reduced acute skin toxicity and maintaining proper tumor response. These early results indicate that SIB is a favorable option for managing head and neck cancers.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"194-204"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-induced malignancies from simultaneous integrated boost-VMAT for oropharyngeal cancer delivered with four different fractionation schemes.","authors":"Michalis Mazonakis, Efrossyni Lyraraki, John Damilakis","doi":"10.5603/rpor.110470","DOIUrl":"10.5603/rpor.110470","url":null,"abstract":"<p><strong>Background: </strong>Late side-effects including carcinogenesis may appear following head-and-neck tumor irradiation. This study estimated the risk for developing second malignancies in heavily exposed tissues from simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) for oropharyngeal carcinoma.</p><p><strong>Materials and methods: </strong>Sixteen oropharyngeal carcinoma patients needing bilateral neck irradiation were included. A three-level SIB-VMAT technique with 6-MV photons was applied. Four different treatment plans were created per patient. The first plan (VMAT_70Gy) was generated based on conventional fractionation delivering total doses to three targets of 70/63/56 Gy in 35 fractions. The VMAT_66Gy, VMAT_60Gy and VMAT_56.7Gy plans gave target doses of 66/60/54 Gy in 30 fractions, 60/56/50 Gy in 25 fractions and 56.7/52.5/46.2 Gy in 21 fractions, respectively. Differential dose-volume-histograms and a non-linear model were employed to estimate the lifetime attributable risk (LAR) for cancer induction in critical tissues adjacent to the treatment volume. The model accounted for dose fractionation and tissue-dependent proliferation ability.</p><p><strong>Results: </strong>For 50-year-old males and females undergoing VMAT_70Gy, the average LAR for cancer induction in thyroid, salivary glands, mouth/pharynx and brain/CNS was up to 0.25%, 0.26%, 1.32% and 0.31%, respectively. The risk range for patients aged 60 years was 0.09-0.74%. These LARs were reduced up to 4.3%, 8.0% and 13.1% with VMAT_66Gy, VMAT_60Gy and VMAT_56.7Gy plans_, respectively. The three moderately hypofractionated radiotherapy techniques led to cancer risks of 0.08-1.27%.</p><p><strong>Conclusions: </strong>The risks for radiation-induced malignancies following SIB-VMAT for oropharyngeal cancer were found to be comparable with the baseline risks for general population. Hypofractionated treatment restricted the probability for carcinogenesis.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"205-213"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-induced brachial plexopathy in a patient with <i>ATM</i> mutation following radiochemotherapy for grade 2 invasive ductal breast carcinoma.","authors":"Anna Gil, Justyna Bochenek-Cibor","doi":"10.5603/rpor.109092","DOIUrl":"10.5603/rpor.109092","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"304-306"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of diabetes mellitus in patients undergoing radiation therapy for head and neck cancer.","authors":"Silpa Johnson, Sandeep Muzumder, Hadrian Noel Alexander F, Nirmala Srikantia, Avinash H Udayashankara, Swathi R Krishna, Deepu C Tom, John M Raj","doi":"10.5603/rpor.110811","DOIUrl":"10.5603/rpor.110811","url":null,"abstract":"<p><strong>Background: </strong>The study aims to find the impact of diabetes mellitus (DM) in patients undergoing radiation therapy (RT) for head and neck cancer (HNC).</p><p><strong>Materials and methods: </strong>The retrospective cohort study analysed 346 HNC patients who received definitive or adjuvant RT with or without chemotherapy from January 2013 to December 2023. The patients were categorized into DM (n = 84) and non-DM (n = 262) group. This study analysed baseline characteristics, compliance, toxicities, and overall survival (OS).</p><p><strong>Results: </strong>A total of 12 (14.3%) patients in the DM arm and 24 (9.2%) in the non-DM arm did not complete the scheduled RT. Treatment breaks (> 2 days) occurred in 49 patients (58.3%) in the DM arm <i>vs</i>. 87 (33.2%) in the non-DM arm. Grade ≥ 3 acute toxicities were significantly frequent in the DM arm, including mucositis (61.9% <i>vs</i>. 42.7%), dysphagia (44.0% <i>vs</i>. 26.0%), pain (53.6% <i>vs</i>. 40.1%), febrile neutropenia (34.5% <i>vs</i>. 24.4%), and infections (66.7% <i>vs</i>. 54.2%). Supportive interventions were also significantly higher in the DM arm: antibiotics (60.7% <i>vs</i>. 45.4%), antifungals (51.2% <i>vs</i>. 39.7%), feeding procedures (33.3% <i>vs</i>. 16.8%), hospitalizations (58.3% <i>vs</i>. 40.1%), and Intensive care unit (ICU) admissions (4.8% <i>vs</i>. 2.3%). After 17.15 months' follow-up, mortality was 47.6% in DM <i>vs</i>. 35.1% in non-DM (p = 0.040), with median OS 35.3 months in DM and not reached in non-DM. Restricted mean survival was significantly higher in the non-DM group (42.3 <i>vs</i>. 34.3 months; p = 0.0059).</p><p><strong>Conclusions: </strong>This study showed that HNC patients with DM undergoing RT are more susceptible to acute and late toxicities, poor compliance to treatment and significantly poor OS compared to non-DM group.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"175-185"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective study on dose escalation using intensity modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) and concurrent chemotherapy in preoperative locally advanced rectal cancer.","authors":"Sattama Samanta, Kaustav Chatterjee, Subrata Chatterjee, Sk Toslim Hossain, Sattwik Basu","doi":"10.5603/rpor.110098","DOIUrl":"10.5603/rpor.110098","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemoradiotherapy (NACTRT) with 45-50.4 Gy in 25-28 fractions, followed by total mesorectal excision and adjuvant chemotherapy is a standard treatment option for locally advanced rectal cancers (LARC). Literature has showed benefit in terms of tumour downstaging and pathological complete response (pCR) rates with radiotherapy dose escalation. The aim of our prospective single-arm study was to analyse the role of this dose escalation, using intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) in LARC.</p><p><strong>Materials and methods: </strong>Fifty-two patients of LARC included in the study were treated with NACTRT. Pelvic nodes and primary disease received 45 Gy/25 fractions along with SIB to the gross disease, to a total dose of 52 Gy, along with concurrent capecitabine. Six weeks post-NACTRT, patients underwent pelvic magnetic resonance imaging (MRI) for response assessment and were sent for surgery six-eight weeks after completion of NACTRT, followed by Adjuvant chemotherapy after surgery. Post-op histopathological report was analysed and patients underwent 3-monthly follow up to further ascertain any local recurrences or distant metastasis, disease free survival (DFS) and dose-escalation related toxicities.</p><p><strong>Results: </strong>Post-NACTRT response evaluation done with Pelvic MRI suggested a complete response or near complete response in 36.54% patients, while sphincter preservation surgery was feasible in 42.30% patients. R0 resection, T and N downstaging, pCR was observed in 94%, 68%, 36% and 26% patients, respectively. The Grade-3 toxicity rates were acceptable. One-year-DFS was 91.84%.</p><p><strong>Conclusions: </strong>It may be safely concluded that dose-escalated NACRT delivered using IMRT-SIB technique in LARC patients offers decent rates of pCR with acceptable toxicity rates.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"239-249"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of postoperative stereotactic ablative radiotherapy <i>vs</i>. conventional fractionation in head and neck sarcomas.","authors":"Alper Kahvecioglu, Mervenur Bay, Mustafa Cengiz, Sezin Yuce Sari, Oguz Kuscu, Ibrahim Gullu, Gozde Yazici","doi":"10.5603/rpor.109517","DOIUrl":"10.5603/rpor.109517","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the efficacy and safety of conventional fractionated radiotherapy (CFRT) and stereotactic ablative radiotherapy (SABR) in the postoperative management of head and neck sarcomas.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 40 patients with resected head and neck sarcomas who had received postoperative radiotherapy with either CFRT (n = 30) or SABR (n = 10). The median radiation dose was 35 Gy (range: 24-40 Gy in 3-5 fractions) for SABR and 62 Gy (range: 60-70 Gy in 30-35 fractions) for CFRT.</p><p><strong>Results: </strong>Median follow-up was 60 months. Five-year overall survival (OS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were comparable between the CFRT and SABR groups. In multivariate analysis, R2 resection was independently associated with worse OS (p = 0.02) and DMFS (p = 0.02). Both R2 resection (p = 0.009) and tumor size ≥ 5 cm (p = 0.01) were identified as independent predictors of poorer LRFS. The overall incidence of grade ≥ 3 late toxicity was 10%, with no significant difference between SABR and CFRT (p = 0.25). Notably, three of the four severe toxicity events occurred in patients with tumors involving the orbit.</p><p><strong>Conclusions: </strong>CFRT remains the established postoperative standard for head and neck sarcomas. Our findings suggest that SABR may also be considered for carefully selected patients, although its use requires caution in anatomically sensitive locations such as the orbit. Further prospective studies are needed to confirm its safety and to better define patient selection criteria.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 2","pages":"167-174"},"PeriodicalIF":1.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}